On September 24, Viking Therapeutics fell 8.3% in after-hours trading, trading at $38.49/share, with turnover of approximately $9.89 million. The pullback followed two consecutive sessions of sharp gains driven by positive clinical data for its obesity drug candidate VK2735.

The sell-off reflects profit-taking pressure after the stock surged over 34% on September 22 and extended gains intraday on September 24, reaching $43.07. The rally was triggered by the company's announcement that its GLP-1/GIP dual agonist VK2735 demonstrated superior weight maintenance under reduced dosing frequency. Specifically, patients switching from weekly to biweekly injections preserved up to 97% of initial weight loss, while those on monthly dosing retained approximately 90%. Placebo comparators retained only about 61%. At the weekly 17.5mg dose, placebo-adjusted weight loss reached 22% at week 33.

While the clinical data validated VK2735's competitive positioning in the expanding obesity therapeutics market, the magnitude of the preceding rally created conditions for near-term consolidation. The company plans to explore oral dosing regimens in the next phase of the study.

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders, with VK2735 as its lead obesity candidate in both injectable and oral formulations.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)